Source: Associated Press
By: Johnson, Linda A.
Pfizer’s Prevnar 13 vaccine protected senior citizens against pneumonia, blood, and other infections, the drug company said Wednesday. The CAPiTA study, which involved about 85,000 individuals ages 65 or older, found that vaccine recipients saw about 46 percent fewer cases of pneumonia and 75 percent less cases of invasive pneumococcal disease compared to those receiving a placebo. The vaccine protects against 13 strains of pneumococcal disease and is approved in the United States for children ages six weeks to 17 years old and adults 50 years and older.
Copyright © 2014 Information, Inc.